Home › Pheochromocytoma › California › Los Angeles
Pheochromocytoma clinical trials in Los Angeles, CA
3 studies for Pheochromocytoma are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RecruitingPhase 2
- Cedars-Sinai Medical Center ( Site 0110), Los Angeles
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Children's Hospital Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Mattel Children's Hospital UCLA, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RecruitingPhase 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
About Pheochromocytoma
Pheochromocytoma is a rare tumor. Pheochromocytomas often cause the adrenal gland to make too many hormones. This can lead to high blood pressure.
More about Pheochromocytoma on MedlinePlus
Pheochromocytoma trials in other cities
- Washington, DC9 studies
- Philadelphia, PA3 studies
- Chicago, IL3 studies
- Nashville, TN3 studies
- Cedar Rapids, IA3 studies
- Baltimore, MD3 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.